Zobrazeno 1 - 10
of 20
pro vyhledávání: '"R Malamet"'
Autor:
Michael Becker, R Malamet, K Bos, Puja P. Khanna, Robert T. Keenan, William B. White, J Hu, J Li
Publikováno v:
Poster Presentations.
Background Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment of hyperuricemia associated with gout in patients who have not achieved target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af2d79f0f4f19406ae5ea424b816a3c
https://doi.org/10.1136/annrheumdis-2017-eular.3674
https://doi.org/10.1136/annrheumdis-2017-eular.3674
Autor:
J Hu, K. Saag, R Malamet, Diana Jalal, Robert Terkeltaub, Michael H. Pillinger, David S. Goldfarb, K Bos, J Li
Publikováno v:
Poster Presentations.
Background Lesinurad (LESU) is a selective uric acid reabsorption inhibitor approved in the United States and European Union at a 200 mg daily dose in combination with a xanthine oxidase inhibitor (XOI) for treatment of hyperuricemia associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcfb94360cff1ff3c7aec7e056486bcd
https://doi.org/10.1136/annrheumdis-2017-eular.4632
https://doi.org/10.1136/annrheumdis-2017-eular.4632
Publikováno v:
Annals of the Rheumatic Diseases. 72:A703.3-A704
Background Pegloticase was recently approved in the EU for severe debilitating chronic tophaceous gout in patients refractory or with intolerance to xanthine oxidase inhibitors. The pegloticase development program included 2 replicate randomized, pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::644a080e47da666d01f0714f9c94f176
https://doi.org/10.1136/annrheumdis-2013-eular.2080
https://doi.org/10.1136/annrheumdis-2013-eular.2080
Publikováno v:
The Journal of rheumatology. 14(2)
In order to determine the acute effect of nifedipine, a calcium channel blocker, on digital hemodynamics in patients with Raynaud's phenomenon, we studied 21 patients in a double blinded, placebo controlled trial. Digital blood flow at room temperatu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4919635bff24c254f34b080b68e25d38
https://pubmed.ncbi.nlm.nih.gov/3298649
https://pubmed.ncbi.nlm.nih.gov/3298649
Publikováno v:
The Journal of rheumatology. 10(2)
We evaluated the signs and symptoms suggestive of osteoarthritis (OA) of the knee in 682 elderly people. The results suggest that both the frequency of signs and symptoms and the degree of severity remain constant in the 7th, 8th and 9th decades. Dif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2cfe9df663e8b49c5d637ac66ae9f293
https://pubmed.ncbi.nlm.nih.gov/6864681
https://pubmed.ncbi.nlm.nih.gov/6864681
Publikováno v:
Arthritis and rheumatism. 30(3)
A new calcium channel blocker, nicardipine, was studied for treatment of Raynaud's phenomenon in a double-blind, placebo-controlled, crossover trial during the winter months. Clinical response was assessed by a patient-kept diary of symptoms and fing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7d49732ececca50cbff0e605b1b243c
https://pubmed.ncbi.nlm.nih.gov/2952125
https://pubmed.ncbi.nlm.nih.gov/2952125
Publikováno v:
The Journal of rheumatology. 14(4)
Twenty-five patients with Raynaud's phenomenon had serial cold challenges during a double blinded drug trial. The data were analyzed to determine the reproducibility of cold provocation in the induction of critical closure of the digital artery in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e651a27e73caacc3b82a67c0485203a4
https://pubmed.ncbi.nlm.nih.gov/3668980
https://pubmed.ncbi.nlm.nih.gov/3668980
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.